X4 Pharmaceuticals Gets FDA Approval for Xolremdi Capsules
By Chris Wack
X4 Pharmaceuticals said that the Food and Drug Administration approved Xolremdi capsules for use in patients 12 years of age and older with WHIM syndrome to increase the number of circulating mature neutrophils and lymphocytes.
The company said Xolremdi is the first therapy specifically indicated in patients with WHIM syndrome, an ultra-rare and difficult-to-diagnose primary immunodeficiency in which the body's immune system does not function properly, and has trouble fighting infections. WHIM refers to Warts, hypogammaglobulinemia, immunodeficiency, myelokathexis.
The FDA granted Breakthrough Therapy Designation to Xolremdi in WHIM syndrome and evaluated the New Drug Application under Priority Review, a designation for therapies that have the potential to provide significant improvement in the treatment, diagnosis, or prevention of serious conditions.
With the FDA approval of Xolremdi, X4 has received a Rare Pediatric Disease Priority Review Voucher that can be used to obtain priority review for a subsequent application or sold to another drug sponsor.
Write to Chris Wack at chris.wack@wsj.com
(END) Dow Jones Newswires
April 29, 2024 07:06 ET (11:06 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
Q3 in Review and Q4 2024 Market Outlook
-
Top-Performing Stock ETFs of the Quarter
-
September Jobs Report Forecasts Show Moderate Hiring Gains
-
Port Strike a Headache for Shippers but a Potential Tailwind for Certain US Transport Stocks
-
13 Charts on Q3′s Roller-Coaster Rally for Stocks and Bonds
-
5 Stocks to Buy Instead of Overpriced US Equities
-
Q4 Stock Market Outlook: Where We See Opportunities for Investors
-
Markets Brief: Non-Farm Payrolls in the Spotlight Again
-
What the Election Could Mean for Big Tech Stocks
-
3 Lessons From Recent Stock Market Drama
-
Consumer Cyclicals: Even Amid Moderating Consumer Spending, We See Discounts
-
Healthcare: Valuations Look Fair Overall, With Select Industries Still Undervalued
-
Utilities: Falling Interest Rates, Growth Outlook Boosting Stocks
-
Real Estate: Performance Continues to Be Driven by Interest-Rate Movements
-
Financial Services: Sector Doing Well Heading Into Rate-Cutting Cycle
-
Energy: OPEC Faces Hard Supply Decision in Latter Half of 2024